Compare RBB & ETON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | RBB | ETON |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 330.2M | 498.8M |
| IPO Year | 2017 | 2018 |
| Metric | RBB | ETON |
|---|---|---|
| Price | $22.21 | $15.83 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 3 | 3 |
| Target Price | $22.33 | ★ $29.67 |
| AVG Volume (30 Days) | 57.5K | ★ 282.6K |
| Earning Date | 02-02-2026 | 11-06-2025 |
| Dividend Yield | ★ 2.88% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.49 | N/A |
| Revenue | ★ $104,588,000.00 | $70,316,000.00 |
| Revenue This Year | $20.23 | $113.27 |
| Revenue Next Year | $10.98 | $36.70 |
| P/E Ratio | $14.96 | ★ N/A |
| Revenue Growth | N/A | ★ 102.77 |
| 52 Week Low | $14.40 | $11.09 |
| 52 Week High | $23.50 | $23.00 |
| Indicator | RBB | ETON |
|---|---|---|
| Relative Strength Index (RSI) | 73.59 | 41.62 |
| Support Level | $21.77 | $15.75 |
| Resistance Level | $21.65 | $17.19 |
| Average True Range (ATR) | 0.50 | 0.73 |
| MACD | 0.12 | 0.05 |
| Stochastic Oscillator | 88.49 | 35.08 |
RBB Bancorp operates as a bank holding company. It provides various banking products and services such as checking, savings, money market accounts, and certificates of deposits. Its Specific services include remote deposit, E-banking, mobile banking, commercial and investor real estate loans, business loans and lines of credit, Small Business Administration (SBA) 7A and 504 loans, mortgage loans, trade finance, and a full range of depository accounts. It generates its revenue from interest received on loans and leases and, to a lesser extent, from interest received on investment securities and derives income from noninterest sources, such as fees received in connection with various lending and deposit services, loan servicing, gain on sales of loans, and wealth management services.
Eton Pharmaceuticals Inc is a United States based specialty pharmaceutical company. The company is engaged in developing and commercializing pharmaceutical products to fulfill an unmet patient need. It has four commercial rare disease products, Alkindi Sprinkle for the treatment of adrenocortical insufficiency; Carglumic Acid for the treatment of hyperammonemia, Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of hereditary tyrosinemia type 1 (HT-1). The Company has three additional product candidates in late-stage development: ET-400, ET-600, and ZENEO hydrocortisone autoinjector.